首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1902511

神經生物標記市場規模、佔有率及成長分析（按類型、應用、最終用戶和地區分類）－2026-2033年產業預測

Neurological Biomarkers Market Size, Share, and Growth Analysis, By Type (Genomic, Proteomic), By Application (Alzheimer's Disease, Parkinson's Disease), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，神經生物標記市場規模將達到 79.1 億美元，到 2025 年將達到 89.9 億美元，到 2033 年將達到 249.2 億美元，在預測期（2026-2033 年）內，複合年成長率為 13.6%。

神經生物標記在多種疾病的診斷中至關重要，包括自閉症、帕金森氏症和憂鬱症。它們涵蓋代謝體學、影像學、基因組學和蛋白質組學，有助於擴展治療方法選擇、實現早期診斷和非侵入性檢測。這些生物標記為製藥公司提供寶貴的見解，進而改善臨床試驗決策，進一步推動市場需求。隨著個人化醫療的進步，神經退化性疾病的神經生物標記研究正在迅速發展，並推動生物製藥產業從研發轉向商業化。支持健康差異研究的機構增加的資金投入有望促進市場擴張，凸顯了這些生物標記在推動產業診斷和治療領域創新與成長方面的重要作用。

全球神經生物標記市場按類型、應用、最終用戶和地區進行細分。按類型分類，可分為基因組學、蛋白質組學、代謝體學、影像學和其他。按應用分類，可分為阿茲海默症、帕金森氏症、多發性硬化症、泛自閉症障礙和其他。依最終使用者分類，可分為醫院/醫院檢查室、獨立臨床診斷中心、研究機構和其他。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

神經生物標記市場促進因素

生物標記在指示各種健康狀況和疾病方面發揮關鍵作用。癌症發生是一個複雜的多步驟過程，涉及眾多分子通路，使得癌症的診斷、預後和治療極為複雜。因此，僅依賴單一生物標記是不夠的，因為每種癌症類型都具有獨特的分子特徵。新生物標記的發現有助於開發針對癌症相關特定失調的標靶治療。隨著癌症發病率的持續上升，生物標記研究日益受到關注，預計這將顯著推動神經生物標記市場的成長。

限制神經生物標記市場的因素

神經生物標記市場面臨阻礙成長的重大挑戰，主要原因在於生物標記研究的複雜性。整合快速發展且多樣化的資料集構成了巨大的障礙，因為生物標記資訊通常來自多個平台，包括傳統血液檢測、次世代定序和螢光雜合反應。此外，缺乏標準化的報告方法，特別是針對次世代定序檢測，使得採用不同調查方法的機構之間難以進行資料解讀和總結。另外，不同種族、民族和經濟群體在生物標記檢測方面的差異進一步限制了數據的可及性和整體性。

神經生物標記市場趨勢

由於大量資金湧入促進研發，神經生物標記市場正經歷顯著成長。來自各組織和政府機構的投資不斷增加，推動了對阿茲海默症和腦衰老等疾病的創新研究。這些資金有助於尋找具有提高診斷準確性和治療效果潛力的新型生物標記。尤其值得一提的是，旨在消除神經退化性疾病健康差異的努力正日益受到關注，這提升了生物標記在臨床應用中的重要性。這一趨勢不僅加速了研究進展，也拓展了神經生物標記領域的市場格局。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Quanterix Corporation
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
QIAGEN NV
Bio-Rad Laboratories, Inc.
Merck KGaA
F. Hoffmann-La Roche Ltd
Bio-Techne Corporation
Alector Inc.
Banyan Biomarkers, Inc.
Charles River Laboratories International, Inc.
Cisbio
C2N Diagnostics
ImmunArray
Euroimmun AG
Cerebrospinal Fluid Diagnostics
Abbott Laboratories

簡介目錄

Product Code: SQMIG35A2399

Neurological Biomarkers Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.99 Billion in 2025 to USD 24.92 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

Neurological biomarkers are pivotal in diagnosing various conditions, including autism, Parkinson's disease, and depression. They encompass metabolomics, imaging, genomics, and proteomics, facilitating enhanced treatment options, earlier diagnoses, and non-invasive testing methods. The demand for these biomarkers is further propelled by the valuable insights they provide for pharmaceutical companies, improving clinical trial decision-making. As personalized medicine evolves, research in neurological biomarkers for neurodegenerative diseases is rapidly advancing, transforming the biopharmaceutical landscape from R&D to commercial sectors. Increased funding from organizations supporting health disparity research is likely to foster market expansion, highlighting the critical role of these biomarkers in driving innovation and growth across diagnostics and therapeutic domains within the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segments Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

Biomarkers play a crucial role in indicating various health conditions and diseases. The intricate multistage process of carcinogenesis involves numerous molecular pathways, making cancer diagnosis, prognosis, and treatment highly complex. Consequently, relying on a single biomarker is inadequate, as each type of cancer possesses a distinct molecular profile. The discovery of new biomarkers facilitates the creation of targeted therapies that address specific dysregulations associated with cancer. As the incidence of cancer continues to rise, it drives an increased focus on biomarker research, which is anticipated to significantly enhance the growth of the neurological biomarkers market.

Restraints in the Neurological Biomarkers Market

The Neurological Biomarkers market faces significant challenges that hinder its growth, primarily due to the complexities involved in biomarker research. The integration of diverse and rapidly evolving data sets poses a substantial hurdle, as biomarker information is often sourced from a multitude of platforms such as traditional blood tests, next-generation sequencing, and fluorescence in situ hybridization. Additionally, the absence of standardized reporting practices, particularly for next-generation sequencing tests, complicates data interpretation and aggregation among organizations employing various methodologies. Furthermore, disparities in biomarker testing across different racial, ethnic, and economic populations further limit data accessibility and comprehensiveness.

Market Trends of the Neurological Biomarkers Market

The neurological biomarkers market is experiencing significant growth driven by an influx of funding aimed at advancing research and development. Increased investments from various organizations and governmental bodies are fostering innovative studies focused on conditions like Alzheimer's disease and brain aging. These funds are facilitating explorations into novel biomarkers that can enhance diagnostic accuracy and treatment efficacy. In particular, initiatives targeting health disparities in neurodegenerative conditions are gaining traction, thereby elevating the relevance of biomarkers in clinical settings. As a result, this trend is not only accelerating the pace of research but also enhancing market potential within the neurological biomarker landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pipeline Analysis
Penetration and Growth Prospects Analysis
PESTEL Analysis
Patent Analysis

Neurological Biomarkers Market, By Type

Market Overview
Genomic
Proteomic
Metabolomic
Imaging
Others

Neurological Biomarkers Market, By Application

Market Overview
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others

Neurological Biomarkers Market, By End User

Market Overview
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations and Others

Neurological Biomarkers Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Quanterix Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Techne Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alector Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Banyan Biomarkers, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cisbio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
C2N Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunArray
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Euroimmun AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cerebrospinal Fluid Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments